lamivudine; zidovudine - Profile

What are the generic drug sources for lamivudine; zidovudine and what is the scope of patent protection?

Lamivudine; zidovudine is the generic ingredient in two branded drugs marketed by Viiv Hlthcare, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Epic Pharma Llc, Hetero Labs Ltd Iii, Hetero Labs Ltd V, Lupin Ltd, Macleods Pharms Ltd, Natco, Pharmacare, and Pharmobedient, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirteen tentative approvals for this compound.

Summary for lamivudine; zidovudine

US Patents:	0
Tradenames:	2
Applicants:	13
NDAs:	14

Generic filers with tentative approvals for LAMIVUDINE; ZIDOVUDINE

Applicant	Application No.	Strength	Dosage Form
		150MG; 300MG; 600MG	TABLET; ORAL
		150MG; 300MG; 300MG	TABLET; ORAL
		150MG; 300MG; 200MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for lamivudine; zidovudine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997		DISCN	Yes	No
Aurobindo Pharma	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	077558-001	May 5, 2017	AB	RX	No	No
Aurobindo Pharma Ltd	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	202418-001	May 15, 2012		DISCN	No	No
Chartwell Rx	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	079081-001	May 25, 2011		DISCN	No	No
Cipla	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	077411-001	Sep 7, 2018	AB	RX	No	No

EU/EMA Drug Approvals for lamivudine; zidovudine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva Pharma B.V.	Lamivudine/Zidovudine Teva	lamivudine, zidovudine	EMEA/H/C/001236Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.	Withdrawn	yes	no	no	2011-02-28
ViiV Healthcare BV	Combivir	lamivudine, zidovudine	EMEA/H/C/000190Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.,	Authorised	no	no	no	1998-03-18

Lamivudine; zidovudine Market Analysis and Financial Projection

Last updated: February 4, 2026

Investment Scenario and Fundamentals Analysis for Lamivudine and Zidovudine

Market Overview

Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) used in antiretroviral therapy (ART) for HIV/AIDS. Their global sales have been historically driven by the prevalence of HIV worldwide and the continued need for combination therapies. The immediate patent expiry status, generic competition, and evolving treatment guidelines influence their investment potential.

Global Market Size and Trends

• The global market for HIV drugs was valued at approximately $21.3 billion in 2022, with NRTIs comprising a significant share [1].
• Lamivudine and zidovudine account for a combined revenue of roughly $3 billion annually, primarily from established markets in North America, Europe, and parts of Asia.
• Growth in the market is influenced by expanding access in low- and middle-income countries, though price pressure from generics suppresses revenue potential in these regions.

Patent Status and Generic Competition

• Lamivudine's original patent expired in 2008, leading to extensive generic manufacturing. Global revenue today mostly derives from older formulations.
• Zidovudine's patent expired in 2004; generic versions account for the majority of sales. Limited innovation potential remains for these compounds.
• Some formulations, such as fixed-dose combinations (FDCs), are under patent, offering limited new revenue streams.

Clinical and Regulatory Landscape

• Both drugs are listed on WHO's Essential Medicines List, supporting ongoing demand.
• Replacement of monotherapies with fixed-dose combination therapy has become standard, influencing market dynamics.
• Regulatory pathways are straightforward in many jurisdictions due to established safety profiles but limit upside for new developments.

R&D and Pipeline Outlook

• Little R&D is directed toward remaking lamivudine or zidovudine; focus has shifted toward novel agents and integrase inhibitors.
• No recent approvals for new formulations of these drugs, reducing their appeal for innovation-driven investment.
• The potential for combination therapy reformulations may sustain some revenue, but risks include patent challenges and pricing pressures.

Financial and Investment Considerations

• The turnover primarily results from sales of commoditized generics, with margins declining due to price competition.
• For investors, these drugs offer limited growth; returns depend on cost of manufacturing and regional market penetration.
• Emerging markets may present growth opportunities due to expanding access, but margins are lower.

Risks

• Patent expiration reduces exclusivity.
• Price erosion driven by generics limits revenue growth.
• Shifts in treatment guidelines favor newer drugs with better efficacy or tolerability.
• Regulatory changes in different regions impact market access.

Conclusion

Lamivudine and zidovudine no longer represent high-growth segments within HIV pharmacotherapy. The market stabilizes around existing generic sales with minimal R&D activity. Investors seeking growth should consider alternative or adjacent assets with innovation pipelines or market expansion potential.

---

Key Takeaways

• Market growth for lamivudine and zidovudine is stagnant due to patent expirations and generic competition.
• Revenue primarily derives from older formulations sold at low margins.
• Limited scope for new product development diminishes their appeal for future innovation-driven investments.
• Emerging markets offer some upside but come with lower profitability.
• Long-term prospects depend on shifts toward combination therapies and newer antiretroviral agents.

---

FAQs

1. Are lamivudine and zidovudine still valuable for investment?
They are primarily viewed as stable cash-flow assets with declining margins, suitable for investors seeking dependable, low-growth revenue streams rather than high-growth opportunities.

2. Can any new formulations or delivery methods revive their market?
Current development efforts focus on new drugs; reformulations or fixed-dose combinations using these drugs do not significantly extend patent life or revenue potential.

3. What are the main drivers for future revenue of these drugs?
Expanding access in developing markets and maintaining dominance in existing fixed-dose combinations.

4. How does the rise of newer antiretroviral drugs impact lamivudine and zidovudine?
New agents with improved efficacy, safety, and ease of use are replacing older medications, pushing lamivudine and zidovudine toward a declining market.

5. What alternative investments could outperform these drugs?
Innovative drugs targeting resistant HIV strains, long-acting formulations, or biologics with patent protection and better market differentiation.

---

References

[1] IQVIA, "Global HIV Market Report 2022."